Original researchLow proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary
Section snippets
Materials and methods
Between 1988 and 1997, 662 Japanese women with epithelial ovarian cancer underwent primary treatment at the Tottori University Hospital, the Kurume University Hospital, the National Defense Medical College Hospital, and the Jichi Medical School Hospital. Approval for this study was obtained from the Institutional Review Board of Tottori University, School of Medicine. Of 662 patients, 101 patients with dominant or pure clear cell carcinoma and 235 with pure serous adenocarcinoma were observed.
Results
Characteristics of the patients are shown in Table 1. The mean age of patients with clear cell carcinoma was significantly younger than that of those with serous adenocarcinoma (P < .05). Distribution of FIGO stages did not differ between clear cell carcinoma and serous adenocarcinoma (Table 1). The estimated 5-year survival rate for patients with clear cell carcinoma was significantly poorer than that for those with serous adenocarcinoma (20.0% versus 31.9%, P < .001) (Figure 1). The median
Discussion
In the present study, the survival rate for patients with clear cell carcinoma was significantly lower than for patients with serous adenocarcinoma, although age of patients with clear cell carcinoma was younger. Furthermore, patients with clear cell carcinoma had a very low response to chemotherapy and a high incidence of progressive disease. In contrast, patients with serous adenocarcinoma had a high response rate. Goff et al5 also reported a higher incidence of progressive disease with
References (34)
- et al.
Ovarian clear cell adenocarcinoma
Gynecol Oncol
(1989) - et al.
Clear cell carcinoma of the ovaryA study of 59 cases
Gynecol Oncol
(1989) - et al.
Clear cell adenocarcinoma of the ovaryA clinical analysis and comparison with serous carcinoma
Gynecol Oncol
(1989) - et al.
Clear cell carcinoma of the ovaryA distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease
Gynecol Oncol
(1996) - et al.
Clinical characteristics of clear cell carcinoma of the ovary
Gynecol Oncol
(1998) - et al.
DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer
Eur J Cancer
(1992) - et al.
Immunophenotype of ovarian cancer as predictor of clinical outcomeEvaluation at primary surgery and second-look procedure
Gynecol Oncol
(1998) - et al.
Amplification of the mdr1-gene is uncommon in recurrent ovarian carcinomas
Cancer Lett
(1999) - et al.
Molecular mechanisms of multidrug resistance in cancer chemotherapy
Pathol Res Pract
(1996) - et al.
Multidrug resistance protein in recurrent breast cancer
Lancet
(1997)
Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy
Cancer
Clinical characteristics of clear cell carcinoma of the ovaryA distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy
Cancer
cis-Diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells
Cancer Res
Cellular pharmacology of cisplatinPerspectives on mechanisms of acquired resistance
Cancer Cell
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis
Proc Natl Acad Sci USA
Determinants of drug response in a cisplatin-resistant human lung cancer cell line
Jpn J Cancer Res
Cited by (144)
Pretreatment maximum standardized uptake value in 18F-fluorodeoxyglucose positron emission tomography-computed tomography as a prognostic factor for ovarian clear cell carcinoma and low-grade serous carcinoma
2021, Taiwanese Journal of Obstetrics and GynecologyInsights into the role of GPX3, a highly efficient plasma antioxidant, in cancer
2021, Biochemical PharmacologyCitation Excerpt :When GPX3 was suppressed by RNA interference, clear cell adenocarcinoma cells' cisplatin sensitivity increased [70]. Possibly, after GPX3 suppression, clear cell adenocarcinoma cells would have become proliferative and thus enhancing drug accumulation within them [72]. Interestingly, multidrug resistance-associated protein (MRP) and P-glycoprotein (P-gp), associated with multidrug resistance, are not related to cisplatin resistance of clear cell adenocarcinoma.
P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors
2018, Journal of Controlled ReleaseFrom clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer
2024, Journal of Ovarian Research